☆ 4.7 Article

Increased flexibility of the SARS-CoV-2 RNA-binding site causes resistance to remdesivir

PLOS PATHOGENS (2023)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity

Bo Meng et al.

Summary: The Omicron variant of SARS-CoV-2 has a higher affinity for ACE2 and can evade neutralizing antibodies more effectively compared to the Delta variant. A third dose of mRNA vaccine can provide enhanced protection. Omicron has lower replication in lung and gut cells and less efficiently cleaves its spike protein compared to Delta.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

The N501Y spike substitution enhances SARS-CoV-2 infection and transmission

Yang Liu et al.

Summary: The B.1.1.7 variant (Alpha) of SARS-CoV-2 emerged in the UK in the summer of 2020, with 19 mutations including N501Y which is a major determinant of increased transmission. The N501Y substitution increased viral transmission by enhancing the spike protein's affinity for cellular receptors, making it an adaptive spike mutation of concern.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant

Rigel Suzuki et al.

Summary: The Omicron variant of SARS-CoV-2 has spread rapidly in several countries and has shown lower fusogenicity and attenuated pathogenicity compared to the Delta variant.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation

Akatsuki Saito et al.

Summary: During the COVID-19 pandemic, the B.1.617.2/Delta variant has been found to be highly fusogenic and more pathogenic in infected hamsters compared to prototypic SARS-CoV-2. The P681R mutation in the spike protein of this variant enhances viral fusogenicity and pathogenicity.

NATURE (2022)

Add to Collection

Article Multidisciplinary Sciences

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Lihong Liu et al.

Summary: The B.1.1.529/Omicron variant of SARS-CoV-2, initially detected in southern Africa, has rapidly spread globally and is expected to become dominant due to its enhanced transmissibility in the coming weeks. This variant poses a threat to the efficacy of current COVID-19 vaccines and antibody therapies due to its significant antibody resistance. Even individuals who have received vaccines and booster doses may have reduced neutralizing activity against B.1.1.529.

NATURE (2022)

Add to Collection

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Medicine, General & Internal

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Shirley Collie et al.

Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike

Daichi Yamasoba et al.

Summary: Research has shown that the Omicron lineage BA.1 has been outpaced by a new Omicron lineage, BA.2, which is more transmissible. Immunity induced by COVID vaccines does not effectively protect against BA.2, similar to BA.1, and BA.2 has notable antigenic differences from BA.1. BA.2 spike shows higher replication efficacy and cell fusion capability compared to BA.1 spike. Infection experiments on hamsters indicate that BA.2 spike-bearing virus is more pathogenic than BA.1 spike-bearing virus. Overall, these findings suggest that the risk of BA.2 to global health is potentially higher than that of BA.1.

CELL (2022)

Add to Collection

Article Multidisciplinary Sciences

Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa

Juliet R. C. Pulliam et al.

Summary: This study provides two methods for monitoring reinfection trends in routine surveillance data. The results suggest immune evasion by the Omicron variant in previously infected individuals in South Africa, and there has been an increase in the risk of having a third infection since mid-November 2021.

SCIENCE (2022)

Add to Collection

Article Multidisciplinary Sciences

De novo emergence of a remdesivir resistance mutation during treatment of persistent SARS-CoV-2 infection in an immunocompromised patient: a case report

Shiv Gandhi et al.

Summary: This article reports a case of remdesivir resistance mutation in an immunocompromised patient with SARS-CoV-2 infection. The patient developed viral shedding recurrence and whole genome sequencing identified a mutation, E802D, in the nsp12 RNA-dependent RNA polymerase. In vitro experiments showed that this mutation increased remdesivir resistance but had a fitness cost in the absence of remdesivir. The patient achieved sustained clinical and virologic response with casirivimab-imdevimab treatment.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article Cell Biology

SARS-CoV-2 infection triggers paracrine senescence and leads to a sustained senescence-associated inflammatory response

Shunya Tsuji et al.

Summary: This study reveals that SARS-CoV-2 infection can induce senescence-like cell-cycle arrest in neighboring uninfected cells through virus-induced cytokine production. The infected cells continue to express inflammatory factors known as senescence-associated secretory phenotypes even after the virus is no longer detectable. The expression of senescence markers and inflammatory genes is increased in the pulmonary cells of severe post-acute COVID-19 syndrome patients. Senolytic drugs can effectively reduce cellular senescence and inflammation in the lung after SARS-CoV-2 infection.

NATURE AGING (2022)

Add to Collection

Editorial Material Immunology

Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019

Martin Martinot et al.

Summary: A 76-year-old female with post-rituximab B-cell immuno-deficiency and persistent SARS-CoV-2 viremia developed a mutation in RdRP (D484Y) following treatment with remdesivir, but was successfully cured after supplementation with convalescent plasma.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Article Microbiology

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

Allison J. Greaney et al.

Summary: Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are key in neutralizing antibody responses, and a deep mutational scanning method was used to assess the impact of all amino-acid mutations in the RBD on antibody binding with 10 human monoclonal antibodies. The study identified the clustered escape mutations in different surfaces of the RBD that correspond to structurally defined antibody epitopes, showing that even antibodies targeting the same surface can have distinct escape mutations.

CELL HOST & MICROBE (2021)

Add to Collection

Article Multidisciplinary Sciences

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19

Dafydd R. Owen et al.

Summary: PF-07321332, an orally bioavailable SARS-CoV-2 main protease inhibitor, has been discovered with in vitro pan-human coronavirus antiviral activity and excellent off-target selectivity and in vivo safety profiles. This new drug has shown promise in countering the threat of COVID-19 with its oral activity and safety in clinical trials.

SCIENCE (2021)

Add to Collection

Article Pediatrics

Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2

Erika Molteni et al.

Summary: Most school-aged children in the UK with SARS-CoV-2 infection are asymptomatic or experience mild illness, with longer duration and higher symptom burden observed in older children. Persistence of illness is more common in older children, but symptom burden does not increase over time and most recover within 56 days. Children who test negative for SARS-CoV-2 may also experience prolonged illness with higher symptom burden.

LANCET CHILD & ADOLESCENT HEALTH (2021)

Add to Collection

Article Medicine, General & Internal

Vaccine Breakthrough Infections with SARS-CoV-2 Variants

Ezgi Hacisuleyman et al.

Summary: Despite evidence of vaccine efficacy, two fully vaccinated individuals developed mild symptoms of Covid-19 and were infected with variants of SARS-CoV-2. Sequencing of the virus isolates revealed novel mutations, highlighting the potential risk of illness post-vaccination and subsequent infection with variant virus. Efforts to prevent, diagnose, and characterize variants in vaccinated individuals are crucial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cell Biology

Establishment of a reverse genetics system for SARS-CoV-2 using circular polymerase extension reaction

Shiho Torii et al.

Summary: A PCR-based, bacterium-free method has been developed to generate SARS-CoV-2 infectious clones, allowing for a better understanding of the virus through the construction of reporter and mutant viruses.

CELL REPORTS (2021)

Add to Collection

Article Microbiology

SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity

Chihiro Motozono et al.

Summary: Research has shown that certain mutations in SARS-CoV-2 variants can escape HLA-restricted cellular immunity, increase affinity for host cells, promote viral replication, and potentially affect the evolution of viral phenotypes.

CELL HOST & MICROBE (2021)

Add to Collection

Review Microbiology

SARS-CoV-2 variants, spike mutations and immune escape

William T. Harvey et al.

Summary: The evolution of SARS-CoV-2 has been characterized by the emergence of mutations and variants that impact virus characteristics. Manufacturers are preparing for possible updates to vaccines in response to changes in the virus population, and it is crucial to monitor genetic and antigenic changes alongside experiments to understand the impacts of mutations.

NATURE REVIEWS MICROBIOLOGY (2021)

Add to Collection

Article Microbiology

In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2

Agnieszka M. Szemiel et al.

Summary: This study selected drug-resistant SARS-CoV-2 populations with decreased sensitivity to remdesivir (RDV) in vitro, identifying a mutation in NSP12 that decreases RDV sensitivity. There is no evidence of widespread transmission of RDV-resistant mutants among globally circulating SARS-CoV-2 variants. Additionally, emerging SARS-CoV-2 variants showed substitutions at Spike sites corresponding to those identified in vitro, indicating their potential to arise without immune selection.

PLOS PATHOGENS (2021)

Add to Collection

Letter Cell Biology

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Manli Wang et al.

CELL RESEARCH (2020)

Add to Collection

Article Multidisciplinary Sciences

A new coronavirus associated with human respiratory disease in China

Fan Wu et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Timothy P. Sheahan et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Microbiology

An Infectious cDNA Clone of SARS-CoV-2

Xuping Xie et al.

CELL HOST & MICROBE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency

Calvin J. Gordon et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Wanchao Yin et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform

Tran Thi Nhu Thao et al.

NATURE (2020)

Add to Collection

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex

James Chen et al.

CELL (2020)

Add to Collection

Article Infectious Diseases

Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis

Sakiko Tabata et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Pharmacology & Pharmacy

Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase

Ariane J. Brown et al.

ANTIVIRAL RESEARCH (2019)

Add to Collection

Article Biochemical Research Methods

fastp: an ultra-fast all-in-one FASTQ preprocessor

Shifu Chen et al.

BIOINFORMATICS (2018)

Add to Collection

Article Microbiology

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease

Maria L. Agostini et al.

MBIO (2018)

Add to Collection

Article Cell Biology

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

Timothy P. Sheahan et al.

SCIENCE TRANSLATIONAL MEDICINE (2017)

Add to Collection

Article Biochemistry & Molecular Biology

A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3

Pablo Cingolani et al.

FLY (2012)

Add to Collection

Article Immunology

Cluster of Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Virus Infections on a Hospital Ward among Immunocompromised Patients-North Carolina, 2009

Luke F. Chen et al.

JOURNAL OF INFECTIOUS DISEASES (2011)

Add to Collection

Article Biochemical Research Methods

The Sequence Alignment/Map format and SAMtools

Heng Li et al.

BIOINFORMATICS (2009)

Add to Collection

Article Biochemical Research Methods

Fast and accurate short read alignment with Burrows-Wheeler transform

Heng Li et al.

BIOINFORMATICS (2009)

Add to Collection

Article Chemistry, Multidisciplinary

Development and testing of a general amber force field

JM Wang et al.

JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.